Tirzepatide 60mg Metabolism
Lyophilised · HPLC 99.7% · COA online
- Certificate of analysis
- In stock in France
Ordered with its water: shipped in a magnetic box
-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees
No card: each delivery is paid in Bitcoin (extra -5%) or by bank transfer
Your complete kit
The vial alone cannot be used as is. Add what you need to prepare it:
Frequently bought together
Research Use Only (RUO) · Prohibited for human or veterinary use.
Key facts
Protocol and preparation
| Water added | Concentration | Reading marker |
|---|---|---|
| 2 ml | 30 mg/ml | 10 UI = 3 mg |
| 3 ml | 20 mg/ml | 10 UI = 2 mg |
The volume of water does not change the product, only its concentration. Add the water slowly along the vial wall, then swirl without shaking.
Asepsis
Disinfect surfaces and stoppers (70% alcohol).
Solvent
Draw the required volume of bacteriostatic water.
Introduction
Add gently against the vial wall (avoid a direct jet on the powder).
Solubilization
Roll the vial gently. Do not shake vigorously (degradation risk).
Solution storage Once reconstituted: 2-8°C (refrigerator).
Warning Theoretical tool for chemical handling. Does not constitute medical advice.
I open the dilution calculator- The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
- The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
- The vial carries no individual label. That is our standard packaging, not a downgraded vial.
- After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
- The parcel is plain. Nothing on the outside indicates the contents or the brand name.
What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.
SURMOUNT-1 long-cycle plateau 15mg over 52 weeks post-titration, optimized for 60mg format.
Option CTitration: the 60mg is not a starter format (2.5mg = 12.5 units at 20 mg/mL, keep it for maintenance). Recommended multi-format protocol: 1 vial 10mg for initial titration W1-4 (4 weeks at 2.5mg), then 4-week steps at 5, 7.5 and 10mg on the 15, 20 or 30mg formats, then 60mg for maintenance from W17.
Long-cycle monitoringIn addition to the standard panel, add TSH and IGF-1 every 3 months (endocrine axis monitoring), baseline echocardiography then at 6 months (heart rate monitoring +5-10 bpm expected under chronic tirzepatide).
Technical data
- Reconstitution
- 3 ml d'eau → 20 mg/ml. 25 UI = 5 mg ; 37,5 UI = 7,5 mg ; 50 UI = 10 mg. Attention : deux fois plus concentré que les 15, 20 et 30 mg, ne pas reprendre leurs repères.
- Peptide sequence
- YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS-NH2 (X = Aib ; lysine acylée)
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813.45 g/mol
- CAS number
- 2023788-19-2
- Physical form
- Poudre lyophilisée blanche
- Recommended solubility
- Eau bactériostatique, NaCl 0.9%, acide acétique 0.1%
- Storage conditions
- Au réfrigérateur (+2 à +8 °C), à l'abri de la lumière. En poudre, possible au congélateur pour une conservation longue. Une fois préparé : réfrigérateur, jamais au congélateur.
- Use
- Research reagent, in vitro only (RUO)
Mechanism of action
Tirzepatide is the first marketed dual incretin-mimetic agonist. Its 39-residue sequence derives from native human GIP (Glucose-dependent Insulinotropic Polypeptide), with engineered modifications that confer simultaneous high affinity at two G-protein-coupled receptors: GLP-1R and GIPR. Coskun and colleagues (Mol Metab 2018) described the rational design: Aib substitutions at positions 2 and 20 blocking DPP-4 cleavage, and a C20 diacid fatty-acyl chain attached to Lys20 via a gamma-glutamate linker that anchors the molecule to serum albumin and extends the half-life to roughly 117 hours in humans.
Tirzepatide biology is not simply the sum of GLP-1 plus GIP activity. The GIPR-biased sequence (picomolar-range EC50 at GIPR, sub-nanomolar at GLP-1R) creates a qualitatively distinct signaling signature. Willard et al. (JCI Insight 2020) demonstrated that tirzepatide recruits beta-arrestin less strongly at GLP-1R than native GLP-1, producing a bias toward Galpha-s / cAMP signaling that may limit receptor desensitization. At GIPR, conversely, tirzepatide behaves as a full agonist. This signaling architecture partly explains the clinical metabolic superiority observed over single GLP-1 agonists.
Frequently asked questions
How long can reconstituted tirzepatide be stored, and what signs indicate degradation?
The complete guideTirzepatide: complete guide to the GLP-1R / GIPR co-agonist in preclinical researchTechnical dossier on tirzepatide for research use: hybrid GIP-GLP-1 structure, dual GLP-1R/GIPR activation, pharmacokinetics, incretin synergy, DIO and ZDF models, QC analytics. Strictly RUO use.Read the guide 